ursodeoxycholic acid has been researched along with Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kataoka, H; Kondo, M; Mukai, M; Nakanowatari, M; Tomita, T | 1 |
1 other study(ies) available for ursodeoxycholic acid and Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
| Article | Year |
|---|---|
Gradual increase of avacopan dose with concomitant ursodeoxycholic acid use may help avoid the risk of C5a receptor inhibitor-induced liver injury in antineutrophil cytoplasmic antibody-associated vasculitis.
Topics: Aged; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Antibodies, Antineutrophil Cytoplasmic; Chemical and Drug Induced Liver Injury, Chronic; Humans; Immunologic Factors; Male; Microscopic Polyangiitis; Prednisolone; Receptor, Anaphylatoxin C5a; Ursodeoxycholic Acid | 2023 |